OR WAIT null SECS
The warning from the US Food and Drug Administration cites consumer risks and violations.
The US Food & Drug Administration (FDA) issued warning letters to 2 websites that have been illegally selling Schedule II stimulants marketed as Adderall.
The warning letters were sent to Kubapharm.com and Premiumlightssupplier.com, claiming that the drugs being sold on these websites are misbranded and in violation of the Federal Food, Drug, and Cosmetic (FD&C) Act. The FDA also stated that the websites are in violation of the Ryan Haight Online Pharmacy Act (RHA), as they had not registered their online pharmacies with the US Drug Enforcement Administration (DEA). Both websites have been given 15 business days to respond to the agencies with the steps they plan to take to address these violations.1
Because Adderall has a high potential for addiction and abuse, selling it without a prescription, and without the supervision of a licensed health care provider, places consumers at risk for abuse and addiction, as well as other potential harmful effects associated with the drug quality. Similarly, if the drug is being sold illegally, there is no guarantee that the drug is not inauthentic, contaminated, expired, or otherwise harmful.1
“This action underscores the FDA’s commitment to use all available regulatory and compliance tools to stop online businesses illegally selling potentially harmful drug products to consumers,” said FDA Commissioner Robert M. Califf, MD, in a press release. “The illegal sale of prescription drug stimulants online puts Americans at risk and contributes to potential abuse, misuse, and overdose. These particular types of online pharmacies also undermine our efforts to help consumers safely purchase legitimate prescription medicines over the internet. FDA will continue partnering with DEA in an effort to safeguard public health and protect consumers who need access to these important medicines.”
1. FDA and FEA warn online pharmacies illegally selling Adderall to consumers. News release. United States Food & Drug Administration. April 12, 2022. Accessed April 13, 2022.